Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer

Hiraku Itadani1, Hiroko Oshima2, Masanobu Oshima2 and Hidehito Kotani*1,3

Address: 1Oncology Research Department, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Tsukuba, Japan, 2Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan and 3Presidents’s Office and Business Development, Banyu Pharmaceutical Co., Ltd, Tokyo, Japan

Email: Hiraku Itadani - hiraku_itadani@mail1.accsnet.ne.jp; Hiroko Oshima - hoshima@kenroku.kanazawa-u.ac.jp; Masanobu Oshima - oshimam@kenroku.kanazawa-u.ac.jp; Hidehito Kotani* - hidehito_kotani@merck.com

* Corresponding author

Published: 17 December 2009
BMC Genomics 2009, 10:615 doi:10.1186/1471-2164-10-615
This article is available from: http://www.biomedcentral.com/1471-2164/10/615
© 2009 Itadani et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Gastric cancers are generally classified into better differentiated intestinal-type tumor and poorly differentiated diffuse-type one according to Lauren’s histological categorization. Although induction of prostaglandin E2 pathway promotes gastric tumors in mice in cooperation with deregulated Wnt or BMP signalings, it has remained unresolved whether the gastric tumor mouse models recapitulate either of human gastric cancer type. This study assessed the similarity in expression profiling between gastric tumors of transgenic mice and various tissues of human cancers to find best-fit human tumors for the transgenic mice models.

Results: Global expression profiling initially found gastric tumors from COX-2/mPGES-1 (C2mE)-related transgenic mice (K19-C2mE, K19-Wnt1/C2mE, and K19-Nog/C2mE) resembled gastric cancers among the several tissues of human cancers including colon, breast, lung and gastric tumors. Next, classification of the C2mE-related transgenic mice by a gene signature to distinguish human intestinal- and diffuse-type tumors showed C2mE-related transgenic mice were more similar to intestinal-type compared with diffuse one. We finally revealed that induction of Wnt pathway cooperating with the prostaglandin E2 pathway in mice (K19-Wnt1/C2mE mice) further reproduce features of human gastric intestinal-type tumors.

Conclusion: We demonstrated that C2mE-related transgenic mice show significant similarity to intestinal-type gastric cancer when analyzed by global expression profiling. These results suggest that the C2mE-related transgenic mice, especially K19-Wnt1/C2mE mice, serve as a best-fit model to study molecular mechanism underlying the tumorigenesis of human gastric intestinal-type cancers.

Background

Gastric cancers are classically categorized into intestinal type and diffuse type based on Lauren’s histological classification [1]. Intestinal-type gastric cancers are characterized by better differentiated, cohesive and glandular-like cell groups. The intestinal type is progressed through mul-
tiple steps beginning with atrophic gastritis that is followed by intestinal metaplasia, dysplasia and carcinoma [2,3]. Diffuse type corresponds to poorly differentiated, infiltrating and non-cohesive tumor cells. Although diffuse type is not characterized by the multiple proceeding steps, this shows more metastatic phenotype with poorer prognosis.

Several genetic alterations are more frequently observed in either subtype of gastric cancer. Overexpression of ErbB2 is selectively found in intestinal-type tumors and may serve as prognostic marker for tumor invasion [4,5]. ErbB2 expression level was reported to correlate with lymph node or liver metastasis [6,7]. Significant decrease in the expression of E-cadherin (CDH1) has also been described preferentially in diffuse-type gastric cancer ranging from 20% to 90% of frequency [8-10]. The decreased expression of CDH1 is caused by LOH or hypermethylation. Interestingly, hereditary diffuse gastric cancer is caused by germline mutations of CDH1 gene [11,12]. In addition, mutation in adenomatous polyposis coli (APC) which activates Wnt/β-catenin pathway is predominantly found in intestinal-type gastric cancer [13]. Cyclooxygenase-2 (COX-2) that is one of the crucial enzymes to synthesize prostaglandin E₂ is highly up-regulated in intestinal-type cancers compared with diffuse-type ones [14]. These genetic alterations could be used as a hallmark of each type of gastric cancer as well as the histological features.

Genome-wide mRNA expression profiles have identified gene signatures to distinguish intestinal- and diffuse-type gastric cancers. Boussioutas et al. [15] reported that the gene signature distinctive for intestinal type exhibits the up-regulation of proliferation markers related to DNA replication, spindle assembly and chromosome segregation. Down-regulated genes in the signature are associated with epithelial differentiation. Jinawath et al. [16] also developed another gene signature that is differentially expressed between intestinal-type and diffuse-type cancers with Japanese gastric tumor samples. The intestinal-type signature represented enhancement of cell cycle progression, while the genes associate with extracellular matrix (ECM) are deregulated in the diffuse type signature. These signatures could provide opportunities of developing biomarkers to diagnose/distinguish the two types in both clinical and preclinical researches.

Transgenic mice that develop gastric tumors present suitable models to decipher gastric tumorigenesis, and identify novel therapeutic targets. We have previously developed several transgenic mice in which prostaglandin E₂ production pathway is highly activated specifically in gastric mucosa. K19-C2mE mice expressing COX-2 and microsomal prostaglandin E synthase-1 (mPGES-1) develop inflammation-associated hyperplasia [17]. This was mediated through the recruitment of mucosal macrophages. By crossing the K19-C2mE mice with K19-Wnt1 mice, cooperative effect of Wnt1 and PGE₂ on gastric tumorigenesis was investigated. The K19-Wnt1/C2mE mice led to the development of dysplastic gastric adenocarcinoma signifying the importance of the Wnt pathway activation to keep the progenitor cells undifferentiated [18]. To examine the additional effect of the suppression of BMP pathway on the prostaglandin E₂ activation, the compound mice of K19-Nog/C2mE were established. The K19-Nog/C2mE mice cause the development of gastric hamartomas that are morphologically similar to juvenile polyposis (JP) [19]. Although the detailed histological and hypothesis-based molecular analysis implicated the pivotal role of prostaglandin E₂, Wnt and Nog pathway respectively in gastric tumorigenesis, it remains elusive whether the K19-C2mE and its compound transgenic mice show similarity to intestinal type or diffuse type of human gastric cancers when analyzed by non-biased global expression profile.

In order to identify which types of human gastric tumors (intestinal or diffuse type) the C2mE-related mice are more similar to, we compared expression profile of the two types of human gastric cancer with those of K19-C2mE, K19-Wnt1/C2mE, and K19-Nog/C2mE transgenic mice.

Results

Overall gene expression profiles of transgenic animals

We have previously developed several types of transgenic mice in which prostaglandin E₂ pathway is activated. K19-C2mE mice expressing COX-2 and mPGES-1 induce hyperplastic gastric tumors. K19-Wnt1/C2mE mice in which both Wnt and prostaglandin E₂ pathways are activated cause dysplastic gastric tumors. K19-Nog/C2mE mice expressing noggin as well as C2mE develop gastric hamartomas. To provide insight into the molecular mechanism of gastric tumorigenesis, gastric tissues from the transgenic mice and wild-type mice were subject to microarray analysis. Using the Affymetrix GeneChip system, mRNA expression levels were measured for 45,037 probe sets, which represent 21,066 Entrez genes and 5,324 other sequences. Increased expression of introduced gene in each transgenic mouse was observed as reported previously [17-19].

Genome-scale overview of the microarray data revealed that expression changes in the three tumor models of K19-C2mE, K19-Wnt1/C2mE and K19-Nog/C2mE were quite similar, whereas overexpression of Wnt1 only or Nog only led to the expression changes in a small portion of genes (Figure 1). This suggests most of expression changes in the three transgenic mice were caused by the activation of PGE₂ pathway. Hypergeometric test for gene enrichment showed that the genes involved in wound healing and
inflammatory response were significantly condensed with the p-value of $1.5 \times 10^{-21}$ and $4.2 \times 10^{-13}$, respectively, in the gene set changed by the C2mE induction.

**Classification of mouse tumor models under a human gastric cancer subtype**

In order to confirm that the mouse gastric tumor models are similar to human gastric cancer, the expression profiles were compared with those of human cancer samples. First, gene expression data of human breast, lung, colon, and gastric tumors were collected from public domain. To estimate similarity between the mouse gastric tumors and the four types of human cancers, supervised classification of principal component analysis (PCA) was conducted using 1,925 genes which were changed more than two-fold in more than 50 samples of all human samples. The PCA with the selected genes found that mouse gastric samples from C2mE-related mice were most closely clustered to human gastric cancers among the four tissues examined, indicating the global expression changes in the gastric tumors of the transgenic mice resembled those in human gastric cancers (Figure 2).

Next, in order to examine which subtype of gastric cancer shows cross-species similarity, the mouse tumors were compared with human gastric intestinal-type and diffuse-type cancers on the basis of their expression profiles. Previous expression profiling studies of human gastric tumor samples have identified gene signatures that classify the two types. Intestinal and diffuse types are the two major types of cancer classified on the basis of microscopic morphology [1]. Boussioutas et al. [15] showed that proliferation genes were over-expressed in intestinal-type tumors than in diffuse-type tumors; in contrast, extracellular matrix protein genes were up-regulated in diffuse-type compared with intestinal-type tumors. In order to determine which type of human gastric cancer the mouse models are more similar to, we normalized the human data [20] to the average of normal samples, and selected 122 genes which were changed in the opposite direction in
intestinal type and diffuse type [see Additional file 1], to classify intestinal and diffuse types by using the normalized data. The false discovery rate was estimated to be 2.4%. The accuracy of class prediction using this gene set was estimated to be 85% by leave-one-out cross-validation of human samples. We also examined whether this gene set can be used to correctly classify another gastric cancer data set [15]. The test data set included 22 intestinal-type, 35 diffuse-type, and ten normal samples, and was normalized to the average of all normal samples. The error rate was 25% in total, and 29% and 18% in diffuse- and intestinal-type cancers, respectively.

To compare the expression patterns of the signature genes in mouse tumors to those in human gastric cancers, hierarchical clustering analysis was performed with mouse gastric data and human intestinal- and diffuse-type data sets. The expression pattern of our modified signature genes for distinguishing intestinal- and diffuse-type gastric cancers revealed that the gastric tumors from C2mE-related transgenic mice were more similar to intestinal-type human gastric cancers than to diffuse-type human gastric cancers (Figure 3). By linear discriminant analysis, all C2mE-related gastric tumors except one K19-Wnt1/C2mE sample were classified as intestinal-type tumors.

**Expression pattern of the genes frequently deregulated in human gastric cancer in a subtype specific manner**

It is known that amplification or overexpression of some genes are found in a subtype-specific manner. E-cadherin gene mutations or loss are specifically found in diffuse-type gastric cancer [11,12]. In contrast, amplification of ErbB2 gene is observed only in intestinal type, and not reported in diffuse type [6,7]. LOH of deleted in colorectal carcinoma (DCC) is predominantly observed in about half of intestinal-type [21,22]. Expression levels of the three genes were compared between mice and human gastric cancer types (Table 1). CDH1 expression was significantly decreased in human diffuse type but not in intestinal type as expected. In the three transgenic mice, Cdh1 gene was not decreased in any of transgenic mice compared with wild-type, inferring that one of the most characteristic changes in human diffuse type gastric cancer was not observed in the mouse models. Up-regulation of ErbB2 was observed in human intestinal-type microarray data, and also in our mouse data. DCC expression was reduced in human intestinal-type as expected, while the reduction of the gene was observed in the mice model, especially in K19-Wnt1/C2mE mice. The expressions of the three genes defining the tissue-type of the human gastric cancer also support the idea that the mouse models are more similar to intestinal-type human cancer.

**Difference among PGE2 pathway-activated mouse models**

Tumors from three mouse models with PGE2 pathway activation show different histology. K19-C2mE develops hyperplasia with macrophage infiltration, whereas K19-Wnt1/C2mE develops dysplasia [17,18]. K19-Nog/C2mE develops hamartoma similar to human juvenile polyposis [19]. We next attempted to identify differentially expressed genes among the three mouse models which allowed us to assess the best-fit model among the three to study gastric intestinal-type cancer. With ANOVA p-value threshold of 0.001, we selected 155 genes which were differentially regulated among the three groups. Few of these genes showed expression changes in the same direction between K19-Wnt1/C2mE and K19-Nog/C2mE (Figure 4). Wnt pathway genes Porcn, an acyltransferase required for Wnt protein secretion, β-catenin (Ctnnb1), and Tce2a (TCF3 in human) were overexpressed in K19-Wnt1/C2mE
mice, but not in K19-Nog/C2mE (Figure 4). TGF-β/BMP pathway genes Smad3 and Tgfbr2 were also up-regulated and Bmp2 was down-regulated in K19-Wnt1/C2mE but not in K19-Nog/C2mE.

In K19-Nog/C2mE mice, some genes which promote tumorigenesis were up- or down-regulated, although they have not been reported in the downstream of BMP pathway. ROCKII was specifically up-regulated in K19-Nog/C2mE, and its overexpression is associated with progression in several types of cancers via modulating actin cytoskeleton organization. Down-regulated genes include RAMP2 and PPARGC1A, and their inactivation or under-expression was shown to contribute to lung cancer and hepatoma development respectively.

Since deregulation of Wnt pathway including APC or CTNNB1 mutation have been more frequently observed in intestinal-type compared with diffuse-type [23,24], the results indicated that K19-Wnt1/C2mE could offer a model that best-fits intestinal-type tumors among the three C2mE-related mice.

**Discussion**

The present study indicated that human intestinal-type gastric cancers exhibited significant similarity to C2mE-related mice, especially to K19-Wnt1/C2mE mice by global expression profiling. The prediction of similar tumor type by global expression profile is consistent with the phenotypes of the transgenic mice. Accumulating evidence has indicated that inflammation level which is caused by the up-regulated expression/activity of COX-2 and mPGES-1 is severer in intestinal-type gastric cancer compared with diffuse-type one, although both types of tumors are related to Helicobacter pylori that are known to induce inflammation to the infected site [14,25-28]. This knowledge supports our observation that gastric tumors in C2mE-related mice in which PGE2 pathway is activated exhibit similarity to intestinal-type gastric tumors. In addition, activating and inactivating mutations in CTNNB1 and APC are more frequently observed in intestinal-type cancer. No APC LOH/mutation were observed in diffuse-type gastric cancer, whereas 60% were found in intestinal-type one [24,29,30]. Mutation in CTNNB1 was

---

**Table 1:** Expression changes of subtype-specific genes in mouse and human gastric tumors.

|                  | C2mE | Wnt1/C2mE | Nog/C2mE | Diffuse | Intestinal |
|------------------|------|-----------|----------|---------|------------|
| CDH1             | 1.13*| 1.00      | 1.10     | 0.43*   | 1.09       |
| ErbB2            | 1.37*| 1.43*     | 1.25*    | 0.92    | 1.37*      |
| DCC              | 0.91 | 0.85*     | 0.94     | 0.98    | 0.71*      |

Expression values are shown in average log ratios (base 10) to wild-type or normal samples. Asterisk indicates t-test p-value < 0.05.

---

**Figure 4**

*Wnt/β-catenin regulatory genes are up-regulated in Wnt1/C2mE mice.* Clustered in rows are 155 probe sets which were differently regulated among three genotypes, K19-C2mE, K19-Wnt1/C2mE, and K19-Nog/C2mE, using ANOVA p-value threshold 0.001. Columns show mouse gastric sample grouped by genotype and genotypes are shown on top of the heatmap. Color scale is same as in Figure 1.
predominantly observed in intestinal-type one [13]. This
is also concordant with our previous finding that K19-
Wnt1/C2mE mice which only develop adenocarcinoma
among the three C2mE-related mice activate down stream
genes of Wnt/β-catenin pathway.

Usually, several types of transgenic mice for one tumor
type are required to examine similarity in global expres-
sion profiling between mice tumor models and human
ones, since the genes which were up- or down-regulated in
each mice model were extracted compared to the average
of all the examined tumor samples. With this approach,
Lee et al. [31] analyzed gene expression data of seven
mouse hepatocellular carcinomas (HCCs) including five
GEMs with human HCCs to identify models that recapit-
ulate human cancer or a type of human cancer, and found
that some subclasses of human HCC mimic mice models
in expression pattern. Hershkovitz et al. [32] also used the
same normalization method, and found that characteris-
tic expression patterns observed in human breast tumors
were conserved in 13 mouse breast tumor models. Since
the available data of expression profile for mouse gastric
tumors are limited to our K19-C2mE and its compound
mice, we took different strategy to assess the similarity of
gastric tumors between the two species. Instead of using
average of all samples in the dataset as a reference to cal-
culate expression ratios, we normalized the mouse gastric
data to average of wild-type samples. To compare our
mice expression profiles with those of human gastric can-
cers, the gene signature to classify human intestinal- and
diffuse-type gastric cancers was also modified from origi-
nal one by normalizing the expression data to the average
of normal gastric samples. This has allowed us to reveal
that C2mE-related transgenic mice resemble human intesti-
tinal-type gastric tumors in expression profiling.

Comparison of gene expressions between mouse models
showed that simultaneous induction of Wnt1 and PGE₂
deregulated not only gene expression of Ctnmb1 and Porcn
in Wnt signaling but also Smad3 and Tgfr2 in TGF-β/BMP
signaling. Given the crosstalk between TGF-β/BMP and Wnt pathways has been reported in multiple previous
studies, the deregulated expression of the genes in the
additional signaling pathways could be explained by pos-
itive and negative feedback to the pathways from the up-
regulated Wnt signaling. For example, BMP signaling is
known to suppress β-catenin activity in intestinal stem
cells [33]. BMP signaling could be repressed in K19-Wnt1/
C2mE, because Bmp2 expression was significantly down-
regulated. Increase in Smad3 and Tgfrb2 might be resulted
from the negative feedback by BMP signaling suppression,
as demonstrated in a study on TGF-β induced fibrosis
[34]. In contrast to K19-Wnt1/C2mE transgenic mice, expression changes of the Wnt pathway genes were not
observed in K19-C2mE and K19-Nog/C2mE mice. It would
be of great interest to further analyze the crosstalk of sign-
aling pathways in the compound transgenic mice.

Conclusions
Genetically engineered mouse (GEM) models provide
useful tools to study mechanism of tumorigenesis, to val-
idate a new target for drug development, and to find
biomarkers. Advances in genetic engineering have
allowed us to develop a variety of transgenic or knockout
models of human diseases. The main question on using
GEMs as disease models is whether the model recapitu-
lates the human disease. We previously developed several
gastric tumor transgenic mice in which prostaglandin E₂
pathway is activated. Although we conducted detailed his-
tological analysis with the transgenic mice, it remained
elusive whether global molecular changes in the trans-
genic mice reproduce features of human gastric tumors or
not. This report has provided initial evidence that K19-
C2mE and their compound mice, K19-Nog/C2mE, K19-
Wnt1/C2mE, show similarity to human gastric cancer,
especially to intestinal-type one by the analysis of mRNA
expression profile. Among others, extraction of up- or
down-regulated genes specifically in K19-Wnt1/C2mE or
K19-Nog/C2mE respectively inferred that K19-Wnt1/C2mE
mice would provide best-fit mouse model for intestinal-
type gastric tumors. These findings would potentially pro-
vide various benefits in our future studies including eluci-
dation of gastric tumorigenesis and optimal therapeutic
target identification.

Methods
Stomach tissue samples
Construction of transgenic mice have been described in
our previous studies [17-19]. Briefly, the K19-Wnt1 and
K19-Nog strains overexpress Wnt1 and Nog genes, respec-
tively, specifically in the stomach. K19-C2mE over-
expresses the mPGES-1 gene and COX-2 genes simul-
taneously and specifically in the stomach. K19-
Wnt1/C2mE and K19-Nog/C2mE are compound trans-
genic mice with K19-Wnt1 and K19-Nog, respectively;
both mouse strains have K19-C2mE. For expression profil-
ing, three wild-type C57BL/6, five K19-Wnt1, three K19-
C2mE, five K19-Wnt1/C2mE, two K19-Nog, and three K19-
Nog/C2mE mice were used. All animals used in this study
were female mice aged 18-65 weeks. The glandular stom-
ach of each mouse was cut for microarray analysis. All an-
imal studies were carried out in accordance with good
animal practice as defined by the Institutional Animal
Care and Use Committee (IACUC).

Microarrays
GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix,
Inc.) were used to monitor the expression profiles of the
gastric samples. Total RNA was prepared using the RNeasy
Mini Kit (QIAGEN) after treatment with TRIzol (Invitro-
gen Corp.), and labeled cRNA was prepared using standard Affymetrix protocols. The signal intensities of the probe sets were normalized by the Affymetrix Power Tools RMA method implemented in Resolver software (Rosetta BioSoftware), and log ratio values to the average of wild-type samples were calculated for each sample by using Resolver. All the microarray data were deposited at Gene Expression Omnibus (GEO) under dataset accession no. GSE16902 [35].

Public human microarray data

Human gastric cancer [20] and breast cancer [36] microarray data were retrieved from the online supplement in the Stanford Microarray Database [37]. The gastric cancer data includes 68 intestinal-type cancer, 13 diffuse-type cancer, and 15 normal gastric samples. The breast cancer data include 115 breast tumor and seven normal tissue samples. Human colon cancer data [38], including 100 colorectal cancer and five normal tissue samples, were retrieved from NCBI GEO under accession GSE5206. The Ann Arbor lung tumor dataset [39] including 86 lung adenocarcinomas and 10 non-neoplastic lung samples was obtained from the United States National Cancer Institute website [40]. Expression values were transformed to log10 (ratio to geometric averages of normal samples) in order to compare with mouse data.

Intestinal vs. diffuse type signature genes

Human gastric tumor data from Chen et al. [20] were used to develop an intestinal vs. diffuse type classifier. We selected genes that met the following criteria: (1) t-test p-value < 0.001 between the two groups, (2) opposite changes in the average expression of signature genes in intestinal-type tumors and that of signature genes in diffuse-type tumors. The false discovery rate was estimated by the Benjamini and Hochberg method [41]. The tumor classes of mouse and human samples were predicted by linear discriminant analysis using the signature score defined by the following formula:

Signature score = (Average log ratio of genes up-regulated in intestinal-type tumors and down-regulated in diffuse-type tumors) - (Average log ratio of genes down-regulated in intestinal-type tumors and up-regulated in diffuse-type tumors)

Combining mouse and human gene expression data

In order to combine mouse data with human gastric cancer microarray data, mouse and human data were ratioed to the geometric average of wild-type and normal samples, respectively. When there was more than one probe set for a gene in a microarray, the averaged expression ratios were used for the gene. Next, using only homologous genes that are represented in both arrays, we merged the mouse and human data sets into a single data set. The mouse microarray contains 45,037 probe sets, which correspond to 21,066 Entrez genes, and the human microarray contains 6,688 probes, which correspond to 4,463 Entrez genes. When they were merged, 4,094 homologous genes were identified.

Statistical analysis

The hypergeometric test for Gene Ontology enrichment was performed using the Gene Set Annotator developed by Rosetta Inpharmatics [42]. For the other statistical analyses in this study, the MATLAB software (MathWorks Inc.) was used.

Authors’ contributions

MO and HK designed the research. HO constructed the transgenic animals and prepared the stomach tissue samples. HI analyzed the microarray data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Dr. Tsutomu Kobayashi for his assistance in the microarray experiment, and Dr. Shinji Mizuarai for his discussion and comments on the manuscript.

References

1. Lauren P. The two histological main types of gastric carcinoma - diffuse and so-called intestinal-type carcinoma - An attempt at a histo-clinical classification. Acta Pathologica et Microbiologica Scandinavica 1965, 64:31-49.
2. Tahara E: Genetic pathways of two types of gastric cancer. Iarc Sci Publ 2004;327-349.
3. Vauhkonen M, Vauhkonen H, Sipponen P: Pathology and molecular biology of gastric cancer. Best Practice & Research in Clinical Gastroenterology 2006, 20:651-674.
4. Yokota J, Yamamoto T, Miyajima N, Toyoshima K, Nomura N, Sakamoto H, Yoshida T, Terada M, Sugimura T: Genetic alterations of the c-erbB-2 oncoprotein occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988, 2:283-287.
5. Kameda T, Yasui W, Yoshida K, Tsujiyo T, Nakayama H, Ito M, Ito H, Tahara E: Expression of EBBB2 in Human Gastric Carcinomas: Relationship between p185erbB2 Expression and the Gene Amplification. Cancer Research 1990, 50:8002-8009.
6. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miya-zaki I, Yamamoto H: Amplification of the c-met, c-erbB2 and epidermal growth factor receptor gene in human gastric cancers: Correlation to clinical features. Oncology 1998, 55:475-481.
increased early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. European Journal of Gastroenterology & Hepatology 2002, 14:359-363.

35. Wright PA, Williams GT: Molecular biology and gastric carcinoma. Gut 1993, 34:145-147.

36. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira E, Ascano JJ, Frierson H, Moskaluk CA, Harper JC, Roviello F, Jackson P, Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Horii A: Prognostic value of E-cadherin expression in primary adenocarcinoma models and human breast tumors. Genome Biology 2007, 8:R76.

37. He XC, Zhang JW, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zheng X, He X, Wiedemann LM, Mishina Y, Li LH: BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nature Genetics 2004, 36:1117-1121.

38. Zhao Y, Gevder DA: Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-β signaling. Biochemical and Biophysical Research Communications 2002, 294:319-323.

39. Gene Expression Omnis [http://www.ncbi.nlm.nih.gov/geo/]

40. Stanfrod Microarray Database [http://genome-www5.stanford.edu/]

41. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen XD, Haigis K, Jegga AG, Kong S, Sakhivel B, Xu H, Reichling T, Azhar M, Bowman GP, Battersby RB, Bissahoyo AC, Gonzales F, Bloom GC, Eschrich S, Carter SL, Aronow JE, Kleimeyer J, Kleimeyer MC, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM, Doetschman T, Groden J, Dove WF, Threadgill DW, Yeatman TJ, Coffey RJ, Bloom GC, Eschrich S, Carter SL, Aronow JE, Kleimeyer J, Kleimeyer MC, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM, Doetschman T, Groden J, Dove WF, Threadgill DW, Yeatman TJ, Coffey RJ, Aronow JE: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology 2007, 8:R131.

42. Beer DG, Kardia SLR, Huang CC, Giordano TJ, Levin AM, Misek DE, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Lin L, Chen GA, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayashi S, Taylor JMG, Iannettoni MD, Orringer MB, Hanash S: Gene expression patterns predict survival of patients with lung adenocarcinoma. Nature Medicine 2002, 8:816-824.

43. The United States National Cancer Institute website [https://www.cancer.gov/]

44. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995, 57:289-300.

45. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Johnson JM, Rohi CA, van As N, Mehrabian MN, Drake TA, Luisz AJ, Smith RC, Guengerich FP, Strom SC, Schuetze E, Rushmore TH, Ulrich R: Mapping the genetic architecture of gene expression in human liver. PLoS Biology 2008, 6:e107.

Type Gastric Adenocarcinomas. Journal of the National Cancer Institute 1991, 83:640-643.

26. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamashita M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori Infection and the Development of Gastric Cancer. New England Journal of Medicine 2001, 345:784-789.

27. Akhtar M, Cheng TL, Magno RM, Ashktorab H, Smoot DT, Melzer SJ, Wilson KT: Promoter Methylation and Helicobacter pylori-stimulated Cyclooxygenase-2 Expression in Gastric Epithelial Cells. Cancer Research 2001, 61:2399-2403.

28. Yamagata R, Shiomaya T, Fukuda S, Yoshimura T, Tanaka M, Munakata A: Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. European Journal of Gastroenterology & Hepatology 2002, 14:359-363.

29. Wright PA, Williams GT: Molecular biology and gastric carcinoma. Gut 1993, 34:145-147.

30. Lee JS, Grisham JW, Thorgerisson SS: Comparative functional genomics for identifying models of human cancer. Cancergenomics.org 2005, 26:1013-1022.

31. Lee JS, Grisham JW, Thorgerisson SS: Comparative functional genomics for identifying models of human cancer. Cancergenomics.org 2005, 26:1013-1022.

32. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu ZY, Rasmussen KE, Jones LP, Asselin S, Chandrasekharan S, Backlund MG, Yin YZ, Khramtsov AI, Bastein R, Quakkenbush J, Glazer RI, Brown PH, Green JF, Kopelovich L, Furch PA, Palazzo JP, Olopade OJ, Bernard PS, Churchill CD, Perou CM: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology 2007, 8:R76.

33. He XC, Zhang JW, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zheng X, He X, Wiedemann LM, Mishina Y, Li LH: BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-β-catenin signaling. Nature Genetics 2004, 36:1117-1121.

34. Zhao Y, Gevder DA: Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-β signaling. Biochemical and Biophysical Research Communications 2002, 294:319-323.

35. Gene Expression Omnis [http://www.ncbi.nlm.nih.gov/geo/]

36. Stanfrod Microarray Database [http://genome-www5.stanford.edu/]

37. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen XD, Haigis K, Jegga AG, Kong S, Sakhivel B, Xu H, Reichling T, Azhar M, Bowman GP, Battersby RB, Bissahoyo AC, Gonzales F, Bloom GC, Eschrich S, Carter SL, Aronow JE, Kleimeyer J, Kleimeyer MC, Ramaswamy V, Settle SH, Boone B, Levy S, Graff JM, Doetschman T, Groden J, Dove WF, Threadgill DW, Yeatman TJ, Coffey RJ, Aronow JE: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology 2007, 8:R131.

38. Beer DG, Kardia SLR, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen GA, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayashi S, Taylor JMG, Iannettoni MD, Orringer MB, Hanash S: Gene expression patterns predict survival of patients with lung adenocarcinoma. Nature Medicine 2002, 8:816-824.

39. The United States National Cancer Institute website [https://www.cancer.gov/]

40. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995, 57:289-300.

41. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Johnson JM, Rohi CA, van As N, Mehrabian MN, Drake TA, Luisz AJ, Smith RC, Guengerich FP, Strom SC, Schuetze E, Rushmore TH, Ulrich R: Mapping the genetic architecture of gene expression in human liver. PLoS Biology 2008, 6:e107.

42. Beer DG, Kardia SLR, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen GA, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayashi S, Taylor JMG, Iannettoni MD, Orringer MB, Hanash S: Gene expression patterns predict survival of patients with lung adenocarcinoma. Nature Medicine 2002, 8:816-824.